H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ). The total consideration of approximately $935M reflects about a 72% premium to the closing price on March 4, the analyst noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMRX:
- Chimerix downgraded to Neutral from Outperform at Wedbush
- Chimerix Merges with Jazz Pharmaceuticals in $935M Deal
- Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash
- Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M
- Chimerix’s Strategic Pause and Financial Strength Bolster Long-term Buy Rating Amid Regulatory Milestones
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue